

ASX ANNOUNCEMENT

RELEASE OF SHARES FROM VOLUNTARY ESCROW

SYDNEY, Thursday, 5 November 2020: Cellmid Limited (ASX: CDY) advises that, in accordance with ASX Listing Rule 3.10A, 250,000 fully paid ordinary shares will be released from voluntary escrow on 13 November 2020. The shares were issued on 12 November 2018 to Cellmid CEO, Maria Halasz, following shareholders' approval.

The release of these shares does not change the issued capital of the Company.

Approved for release by the Company Secretary.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au. Cellmid's wholly owned subsidiary, Lyramid, develops innovative novel therapies and diagnostic tests for age related diseases including inflammatory and autoimmune conditions. Most recently Cellmid secured access to a range of SARS-CoV-2 antibody and nucleotide tests, both point of care and laboratory based, from various suppliers.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.